Press Releases and Product Information March 23, 2022
advertisement
- Provention Bio Announces FDA Acceptance of the Biologics License Application (BLA) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals
- Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above
- FDA sets August decision date for Provention’s type 1 diabetes drug
- Glooko acquires fellow diabetes management company DIABNEXT and more digital health briefs
- Modular Medical: Next Generation Insulin Pump Developer
- Ypsomed partners with CamDiab Ltd to drive on smartphone based adaptive automated insulin delivery (AID)